UBS lowered the firm’s price target on UiPath (PATH) to $10 from $14 and keeps a Sell rating on the shares. UiPath reported a topline revenue and annual recurring revenue miss, and while profit beat expectations for Q4, the company guided to just $155M in net new ARR for fiscal 2026, down from $202M in fiscal 2025, the analyst tells investors in a research note. UiPath is pointing to impacts from the public sector vertical as well as realized macroeconomic uncertainty in recent weeks as reasons to offer prudent guidance but despite this, UiPath is still banking on a trend change in the second half to achieve 9% ARR growth next year, the firm says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PATH:
- M&A News: UiPath (PATH) Supercharges AI Automation with Peak Acquisition
- UiPath’s Mixed Outlook: Hold Rating Amid Federal Segment Delays and Cloud Growth Potential
- UiPath downgraded to Underperform at BofA on weak outlook, few catalysts
- UiPath price target lowered to $11 from $13 at Wells Fargo
- UiPath’s Financial Outlook Impacted by Delayed Deals and Conservative Growth Forecast Amidst Economic Challenges
Questions or Comments about the article? Write to editor@tipranks.com